ASO Author Reflections: The Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine for Advanced-Stage Melanoma: Reflection on Personalized Cancer Vaccination
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-02-26 / Ann Surg Oncol 2021 10;28(11):6138-6139Modulated Electro-Hyperthermia Facilitates NK-Cell Infiltration and Growth Arrest of Human A2058 Melanoma in a Xenograft Model
/in Hyperthermia, International Publications, Malignant Melanoma /von 2021-02-25 / Front Oncol 2021;11:590764Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2020-04-21 / J Transl Med 2020 04;18(1):176[The adjuvant killing effect of modulated electro-hyperthermia combined with chemotherapy on B16F10 melanoma cells]
/in Hyperthermia, International Publications, Malignant Melanoma /von 2020-02-21 / Magy Onkol 2021 Mar;65(1):71-77TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma /von 2020-02-01 / J Immunother Cancer 2020 02;8(1)Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines
/in Dendritic Cells, Malignant Melanoma /von 2020-01-31 / Biomed. Pharmacother. 2020 May;125:109966Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2020-01-24 / Cancer Immunol. Immunother. 2020 Mar;69(3):477-488Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-11-15 / Hum Vaccin Immunother 2020 04;16(4):742-755Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-10-11 / Biomedicines 2019 Oct;7(4)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de